Prognostic value of circulating tumor cells in oligorecurrent hormone‐sensitive prostate cancer patients undergoing stereotactic body radiation therapy
The Prostate · 2024
DOI: 10.1002/pros.24787 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, 2024. Verfasst von Fabio Matrone und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Radiation Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy. Hauptthemen laut MEDLINE: Neoplastic Cells, Circulating, Radiosurgery, Prostatic Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministero della Salute.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Stereotactic body radiation therapy (SBRT) is an effective metastasis‐directed therapy for managing oligometastatic prostate cancer patients. However, it lacks reliable biomarkers for risk stratification. Circulating Tumor Cells (CTC) show promise as minimally invasive prognostic indicators. This study evaluates the prognostic value of CTC in oligorecurrent hormone‐sensitive prostate cancer (orHSPC). Methods orHSPC patients with 1‐3 nodal and/or bone metastases undergoing SBRT were enrolled ( N = 35), with a median follow‐up time of 42.1 months. CTC levels were measured at baseline (T0), 1 month (T1), and 3 months (T2) post‐SBRT using a novel metabolism‐based assay. These levels were correlated with clinical outcomes through Cox‐regression and Kaplan‐Meier analyses.
Results
Median CTC counts were 5 at T0, 8 at T1, and 5 at T2 with no significant variation over time. Multivariate analysis identified high (≥5/7.5 mL) T0 CTC counts (HR 2.9, 95% CI 1.3–6.5, p = 0.01, median DPFS 29.7 vs. 14.0 months) and having more than one metastasis (HR 3.9, 95% CI 1.8–8.6, p < 0.005, median DPFS 34.1 vs. 10.7 months) as independent predictors of distant progression‐free survival (DPFS). CTC assessment successfully stratified patients with a single metastasis (HR 3.4, 95% CI 1.1–10.2, p = 0.03, median DPFS 42.1 vs. 16.7 months), but not those with more than one metastasis. Additionally, a combined score based on CTC levels and the number of metastases effectively stratified patients.
Conclusion
The study demonstrates that hypermetabolic CTC could enhance risk stratification in orHSPC patients undergoing SBRT, particularly in patients with limited metastatic burden, potentially identifying patients with indolent disease who are suitable for tailored SBRT interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Radiation Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.
- Department of Cancer Research and Advanced Diagnostics, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Immunopathology and Cancer Biomarkers Units, Aviano, Italy.
- Centro di Riferimento Oncologico di Aviano (CRO), Clinical Trial Office, Scientific Direction, IRCCS, Aviano, Italy.
- Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.
ORCID-Profile: Fabio Del Ben
Förderung
- Ministero della Salute
Zitieren
APA
Matrone, F., Del Ben, F., Montico, M., Muraro, E., Steffan, A., Bortolus, R., Fratino, L., Donofrio, A., Paduano, V., Zanchetta, M., Turetta, M., & Brisotto, G. (2024). Prognostic value of circulating tumor cells in oligorecurrent hormone‐sensitive prostate cancer patients undergoing stereotactic body radiation therapy. The Prostate. https://doi.org/10.1002/pros.24787
Vancouver
Matrone F, Del Ben F, Montico M, Muraro E, Steffan A, Bortolus R, et al. Prognostic value of circulating tumor cells in oligorecurrent hormone‐sensitive prostate cancer patients undergoing stereotactic body radiation therapy. The Prostate. 2024. doi:10.1002/pros.24787
BibTeX
@article{Matrone2024,
author = {Matrone, Fabio and Del Ben, Fabio and Montico, Marcella and Muraro, Elena and Steffan, Agostino and Bortolus, Roberto and Fratino, Lucia and Donofrio, Alessandra and Paduano, Veronica and Zanchetta, Martina and Turetta, Matteo and Brisotto, Giulia},
title = {Prognostic value of circulating tumor cells in oligorecurrent hormone‐sensitive prostate cancer patients undergoing stereotactic body radiation therapy},
journal = {The Prostate},
year = {2024},
doi = {10.1002/pros.24787}
}
EUVIMED